BMC Psychiatry
January 4, 2026
Carl D. Marci, Kruti Joshi, Stevan Geoffrey Severtson et al.
2 citations
Abstract Background Treatment-resistant depression (TRD) is often characterized by inadequate response to ≥ 2 oral antidepressant treatments of adequate dose and duration during a major depressive episode (MDE). Esketamine nasal spray (ESK) was approved by the US Food and Drug Administration in 2019 for TRD in conjunction with an oral antidepressant under a Risk Evaluation and Mitigation...
Journal of comparative effectiveness research
June 9, 2025
Kristin Clemens, Amanda Teeple, Benoit Rive et al.
Aim: Estimate the cost-per-remitter with esketamine nasal spray plus an oral antidepressant (ESK NS + OAD) versus quetiapine extended release plus an oral antidepressant (QTP XR + OAD) among adults with treatment-resistant depression (TRD). Materials & methods: An Excel-based model was developed to estimate the cost-per-remitter for ESK NS + OAD and QTP XR + OAD from the perspective of a US...
Clinical Therapeutics
March 1, 2025
Lisa Harding, Maryia Zhdanava, Amanda Teeple et al.
3 citations
Major depressive disorder with acute suicidal ideation or behavior (MDSI) is a substantial humanistic, economic, and clinical burden on patients. Data on health care resource use (HRU) and costs among patients with MDSI initiated on esketamine nasal spray relative to traditional treatments are limited. This study sought to describe HRU and medical costs of patients with MDSI initiated on...
Drugs - real world outcomes
March 1, 2025
Manish K. Jha, Maryia Zhdanava, Aditi Shah et al.
1 citation
Treatment-resistant depression (TRD) is related to disproportionate unemployment and productivity burden in the USA. The current study describes real-world mental health (MH)-related disability days and costs of patients with TRD initiated on esketamine nasal spray or conventional therapies in the USA. Adults with TRD were selected from Merative™ MarketScan® Commercial database (from January...
Current Medical Research and Opinion
February 1, 2025
Manish K. Jha, Amanda Teeple, Jason Shepherd et al.
Esketamine is an FDA-approved treatment for treatment-resistant depression (TRD) or major depression with acute suicidal ideation or behavior (MDSI). This analysis addressed the lack of data on real-world characteristics of patients with TRD and MDSI or prescribed esketamine. Data were derived from the Adelphi Real World Depression Disease Specific Programme a cross-sectional survey of...
The Journal of Clinical Psychiatry
January 27, 2025
Kristin Clemens, Amanda Teeple, Maryia Zhdanava et al.
2 citations
Objective: This post hoc analysis of the ESCAPE-TRD trial compared work productivity loss (WPL) and related costs among patients with treatment-resistant depression (TRD) receiving esketamine nasal spray or quetiapine extended release in combination with an oral antidepressant. Methods: Adults with TRD randomized to receive esketamine (56/84 mg) or quetiapine (150-300 mg) combined with ongoing...
Journal of managed care & specialty pharmacy
2025
Kristin Clemens, Maryia Zhdanava, Amanda Teeple et al.
4 citations
Disparities in mental health care access and health outcomes based on sociodemographic factors in the United States have been extensively documented. However, there is limited knowledge regarding these socioeconomic factors with respect to initiation of esketamine nasal spray, a novel therapy for treatment-resistant depression (TRD). To evaluate the association of socioeconomic factors with the...
Current Medical Research and Opinion
September 1, 2024
Lisa Harding, Maryia Zhdanava, Aditi Shah et al.
2 citations
In the United States (US), prescription drug coverage is subject to prior authorization (PA) criteria, which may vary between health plans and may exceed drug label requirements. This study aimed to characterize profiles and treatment history of patients with treatment-resistant depression (TRD) who initiated esketamine nasal spray, by stringency of their health plans' PA criteria relative to...
Drugs - real world outcomes
June 1, 2024
Lisa Harding, Kruti Joshi, Maryia Zhdanava et al.
5 citations
This study aimed to understand treatment patterns, acute healthcare use, and cost patterns among adults with treatment-resistant depression (TRD) who completed induction treatment with esketamine nasal spray in the United States (US). Per label, induction is defined as administration twice a week for 4 weeks, after which maintenance is started on a weekly basis for 4 weeks, and thereafter,...